Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10413181 | 0.89 | CYP4A11 (0.52) | RAB9ANPC1CA1CA2TSHR | |
| SCHEMBL23113546 | 0.86 | ALDH1A1 (0.58) | RAB9ANPC1CA1CA2TSHR | |
| SCHEMBL26023443 | 0.86 | CA1 (0.55) | RAB9ANPC1CA1CA2TSHR | |
| Hydrochloric Acid SCHEMBL27900963 | 0.85 | TSHR (0.58) | RAB9ANPC1CA1CA2TSHR | |
| SCHEMBL10397250 | 0.83 | MAPT (0.61) | RAB9ANPC1CA1CA2TSHR | |
| SCHEMBL15392053 | 0.83 | MAPT (0.61) | RAB9ANPC1CA1CA2TSHR | |
| SCHEMBL21377435 | 0.83 | PTPN1 (0.64) | RAB9ATSHRMAPTALDH1A1KDM4E | |
| SCHEMBL19713688 | 0.83 | CNR2 (0.45) | RAB9ANPC1CA1CA2MAPT | |
| Hydrochloric Acid SCHEMBL16699846 | 0.82 | MAPT (0.60) | RAB9ANPC1CA1CA2TSHR | |
| SCHEMBL13052122 | 0.82 | ACHE (0.66) | RAB9ANPC1CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013196-B1 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2013196-B1 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119685-B2 | Disubstituted aniline compounds | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010184-A1 | [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090221669-A1 | Disubstituted Aniline Compounds | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| EP-2013196-A2 | DISUBSTITUTED ANILINE COMPOUNDS | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127137-A2 | DISUBSTITUTED ANILINE COMPOUNDS | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221669-A1 | Disubstituted Aniline Compounds | TXNRD2, BRDT, HDAC1 | RAB9A 4477/4885NPC1 3426/4885CA1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.